Biotec BetaGlucans receives promising results from animal study
Biotec BetaGlucans AS, a fully owned subsidiary of Biotec Pharmacon ASA, has received an interim data report from the fourth animal study in diabetic mice. An important goal with this study was to investigate the wound healing efficacy of large scale production batches, also including the first validation batch from June 2012. Included in the study was also experimental dry dressing products wherein SBG (soluble beta-glucan) had been incorporated. The results confirm the finding from the former studies on pilot batches of Woulgan Biogel where the full scale products of Woulgan Biogel showed equal healing efficacy as the already reported pilot batches. The study also showed very promising results for the experimental dry dressing product with SBG.
Biotec Pharmacon has in 2012 produced three large scale batches of Woulgan Biogel at the contract manufacturing producer Sanochemia in Austria and the two latest batches, wherein included the first validation batch, were tested in the established wound model in diabetic mice. The interim report received from the study showed that Woulgan Biogel produced at Sanochemia were fully comparable with the initial pilot batches with respect to wound healing efficacy. In the study was also included the first experimental dry dressing wherein SBG had been incorporated. The dressing, a commercially available foam dressing, had been incorporated with aqueous SBG and dried. The healing efficacy of the dressing was compared to a control dressing without SBG, and with the two standard controls as for the Woulgan Biogel product. The data indicate that SBG can contribute significantly to the wound healing efficacy also in dry dressings.
“We are very pleased with these results as they are important in our efforts to secure a robust and commercially attractive product for topical wound healing, and to further develop beta-glucans as a technology platform for wound healing products”, says Svein Lien, CEO of Biotec Pharmacon.
The wound healing performance of the experimental dressing is shown in the attached file.
For further information, please contact:
CEO Svein Lien, tel +47 92289323
CSO Rolf Engstad, tel +47 95941542
About Woulgan® Biogel:
Biotec BetaGlucans, a subsidiary of Biotec Pharmacon, has developed a novel biogel containing the Company's proprietary compound SBG® (Soluble Beta Glucan) for use in wound treatment. The finalized product, Woulgan® Biogel, offers the typical features of a medical device biogel formulation in addition to the biological wound healing enhancing
ability of the SBG® component, considered to be an ancillary medicinal product in the formulation. Woulgan® Biogel is a sterile, homogenous, clear to hazy and viscous biogel containing Water, Glycerol, 2 % SBG®, and Carboxymethylcellulose. The product does not contain preservatives.
Mode of action:
Woulgan® Biogel provides a moist wound healing environment that promotes the natural healing process. Woulgan® Biogel contains a bioactive Soluble Beta Glucan.
The Company has filed for registration of Woulgan® Biogel to be used as a primary dressing for dry or low exuding partial and full thickness dermal wounds within the following indications: diabetic ulcers, pressure ulcers, leg ulcers, graft and donor sites, postoperative
surgical wounds (dermal lesions, trauma injuries or incisions), 1st and 2nd degree burns, abrasions and lacerations.
About Biotec Pharmacon:
Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The wholly owned Biotec BetaGlucans AS focuses on identifying, developing and commercializing innovative products to meet unmet medical needs in wound treatment, cancer and gastroenterology. The company's technology is protected by a large patent portfolio covering amongst others applications of yeast beta-glucans as adjuvants in conjunction with monoclonal antibodies. The subsidiary ArcticZymes AS aspires to become a leading supplier of novel enzymes for diagnostics and genetic research.
More information, visit www.biotec.no.